1Strek M E. Difficult asthma [ J ]. Proc Am Thorac Soc,2006, 3: 116.
2Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society[J]. Am J Respir Grit Care Med, 2000, 162: 2341.
3Barnes P J, Woolcock A J. Difficult asthma[J]. Eur Respir J, 1998, 12(5): 1209.
4Kenyon N J, Jarjour N N. Severe asthma. Clin Rev Allergy Immunol,2003, 25:131 - 149.
5Graziani E, Petroianni A, Terzano C. Brittle asthma [J ]. Eur Rev Med Pharmacol Sci, 2004, 8: 135.
7Cho Y J, Lee K E. Decreased glucocorticoid binding affinity to gluco- corticoid receptor is important in the poor response to steroid therapy of older - aged patients with severe bronchial asthma [ J ]. Allergy Asthma Proc, 2003, 24: 353.
2Holgate ST, Polosa R. The mechanism, diagnosis, and management of severe asthma in adults. Lancet, 2006, 368:780- 793.
3Pacheco-Galvan A. Refractory asthma: the ongoing debate. Arch Bronconeumol, 2006, 42 : 157-159.
4Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med, 2000, 162:2341-2351.
5Chung KF, Godard P, Adelroth E, et al. Difficult/therapyresistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J, 1999, 13: 1198-1208.
6Kroegel C. Global Initiative for Asthma Management and Prevention--GINA 2006. Pneumologie, 2007, 61:295-304.
7Lee JH, Haselkom T, Borish L, et al. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest, 2007, 132:1882- 1889.
8ten Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J, 2005, 26:812-818.
